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Leigh syndromeGenetically deﬁnedmitochondrial deﬁciencies that result in the loss of complex II function lead to a range of clin-
ical conditions. An array of tumor syndromes caused by complex II-associated gene mutations, in both succinate
dehydrogenase and associated accessory factor genes (SDHA, SDHB, SDHC, SDHD, SDHAF1, SDHAF2), have been
identiﬁed over the last 12 years and include hereditary paraganglioma–pheochromocytomas, a diverse group of
renal cell carcinomas, and a speciﬁc subtype of gastrointestinal stromal tumors (GIST). In addition, congenital com-
plex II deﬁciencies due to inherited homozygous mutations of the catalytic components of complex II (SDHA and
SDHB) and the SDHAF1 assembly factor lead to childhood disease including Leigh syndrome, cardiomyopathy and
infantile leukodystrophies. The role of complex II subunit genemutations in tumorigenesis has been the subject of
intensive research and these data have led to a variety of compelling hypotheses. Among the most widely
researched are the stabilization of hypoxia inducible factor 1 under normoxia, and the generation of reactive oxy-
gen species due to defective succinate:ubiquinone oxidoreductase function. Further progress in understanding the
role of complex II in disease, and in the development of new therapeutic approaches, is now being hampered by
the lack of relevant cell and animal models. This article is part of a Special Issue entitled: Respiratory complex II:
Role in cellular physiology and disease.
© 2012 Published by Elsevier B.V.1. Introduction
Mitochondrial function and oxidative phosphorylation via the respi-
ratory chain are among themost fundamental processes of life. Deﬁcien-
cies in mitochondrial function and in the activity of the various protein
complexes of the respiratory chain have been associatedwith a wide va-
riety of clinical conditions [1]. Deﬁciencies of complex II with a deﬁned
genetic basis have been identiﬁed in only a limited number of diseases,
including the hereditary paraganglioma–pheochromocytoma tumor
syndrome, a speciﬁc group of renal cell carcinomas, gastrointestinal
stromal tumors (GIST) primarily associated with Carney–Stratakis syn-
drome, a subset of Leigh syndrome cases, and most recently, infantile
leukoencephalopathy associated with mutations of SDHAF1.
As complex II of the respiratory chain, succinate dehydrogenase
(SDH) is situated at the intersection of the tricarboxylic acid (TCA)
cycle and mitochondrial oxidative phosphorylation; combining these
functions places SDH at the center of the two essential energy produc-
ing processes of the cell. SDH is a heterotetramer and all four protein
subunits, SDHA, -B, -C and -D, have been implicated in disease. Two
recently identiﬁed SDH accessory factors, SDHAF1 and SDHAF2, are
also involved in disease and although clearly essential to the normal
functioning of complex II, their exact functions are still poorly deﬁned.tory complex II: Role in cellular
31 715268285.
sevier B.V.Despite the fact that these proteins are all associatedwith the samepro-
tein complex, mutations lead to clear differences in clinical phenotype.
The molecular basis for this clinical divergence is as yet unknown.
Biochemical and immunohistochemical analyses have demonstrated
that mutations in complex II-related genes often result in the reduction
or loss of a functional enzyme complex, whichmay in turn lead to either
the accumulation of succinate [2] or the generation of reactive oxygen
species (ROS), due to frustrated electron transport [3,4]. Loss of SDH
may also lead to a limited capacity to utilize oxidative phosphorylation
for ATP production [5,6].
2. Paraganglioma–pheochromocytoma syndrome
Hereditary paraganglioma–pheochromocytoma syndrome is charac-
terized by neuroendocrine tumors that originate from both the sympa-
thetic and parasympathetic branches of the autonomic nervous system.
Paragangliomas arise most commonly in the carotid body and the
abdominal paraganglia, but may occur in a wide variety of paraganglia
at other locations. In general, paragangliomas of the head and neck
(HNPGL) rarely lead tomalignancy ormetastases, and growth is general-
ly extremely slow [7]. In contrast, abdominal paragangliomas show rela-
tively frequent malignancy, with a 5-year survival of 34–60% in cases of
malignant tumors [8].
Pheochromocytomas (PC) originate in the sympathetic nervous sys-
tem and while the term is generally reserved for tumors of the adrenal
medulla, some authors include all sympathetic paragangliomas [3]. In
contrast to HNPGL, pheochromocytomas show a more polygamous
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non-complex II genes, including VHL, RET, NF1, TMEM127 and MAX.
Adrenal pheochromocytomas are usually benign but are clinically
important due to the potentially life-threatening hypertensive crises
that may result from the excessive production and secretion of
catecholamines.
Paraganglioma–pheochromocytoma syndrome, with some notable
exceptions, shows a classic Mendelian pattern of dominant inheritance
in families but as with other tumors associated with tumor suppressor
genes, at the cellular level tumor occurrence resembles a recessive dis-
ease with predominantly adult onset. An inherited mutation is initially
silent and carriers are phenotypically normal at birth, but at some point
a chance secondmutation or loss of the remaining normal allele occurs,
and this so-called ‘second hit’ leads to the initiation and growth of a
tumor (Table 1).2.1. SDHD
The identiﬁcation of SDHD demonstrated for the ﬁrst time that
mitochondrial proteins involved in intermediary metabolism could act
as tumor suppressors [9]. Germline mutations in SDHD generally
result in benign HNPGLs but are also associated with sympathetic
paragangliomas and adrenal pheochromocytomas [10]. Carriers of
SDHD mutations have a very high propensity for tumor development
(penetrance), variously estimated at 87–100%, although not all carriers
will develop overt clinical symptoms or even be aware of their tumor
[11–13].
SDHD and SDHAF2 share the same chromosomal location (Ch11)
and show a very unusual pattern of inheritance-dependent expression
of mutations in which carriers develop tumors only when the mutation
is inherited from the father [14,15]. Although this phenomenon resem-
bles genomic imprinting, no evidence of allelic silencing or suppression
of SDHD or SDHAF2has ever been presented [9,16]. Carriers ofmaternal-
ly transmitted SDHD mutations may, very rarely, develop tumors but
only following complex somatic genetic events in the tumor [17]. The
SDHA, -B or -C genes are located on chromosomes 5 (A) and 1 (B and
C) and mutation carriers show no parental effects.
Several hypotheses have been advanced to explain SDHD-linked
parental effects [18–20] but most data support the so-called ‘Hensen
model’ [20–22]. The loss of the entire maternal copy of chromosome
11 in tumors from paternal SDHD mutation carriers is a hallmark of
SDHD-linked paragangliomas. The Hensen model proposes that ma-
ternal chromosomal loss results in the simultaneous deletion of the
SDHD gene and an exclusively maternally expressed gene, producing
a striking parent-of-origin effect [20,21,23]. The similar penetranceTable 1
Complex II associated gene mutations with clinical phenotype.
Complex II associated gene Phenotype/disease
SDHA Leigh syndrome
Wild-type GIST
Paraganglioma/pheochromocytoma
Cardiomyopathy (isolated)
Late-onset optic atrophy, ataxia, myopathy
SDHB Paraganglioma/pheochromocytoma
Renal cell carcinoma
Carney–Stratakis syndrome/GIST
Infantile leukodystrophy
SDHC Paraganglioma/pheochromocytoma
Carney–Stratakis syndrome/GIST
Renal cell carcinoma
SDHD Paraganglioma/Pheochromocytoma
Carney–Stratakis syndrome/GIST
SDHAF1 Infantile leukodystrophy
SDHAF2 Paraganglioma
Data are derived from the TCA Cycle Gene Mutation Database and/or literature. See text foand clinical phenotype of SDHAF2 and SDHD mutation carriers may
be related to the function of the postulated maternally expressed
tumor suppressor gene. An equivalent parental effect is not associat-
ed with the SDHA, -B or -C genes and even if the same maternally
expressed gene plays a role in these tumors, the independent assort-
ment of chromosomes prevents a parent-of-origin effect.2.2. SDHB
The SDHB gene is the most commonly mutated of all the
SDH-related genes and SDHB mutation carriers may develop extra-
adrenal paragangliomas, adrenal pheochromocytomas or head and
neck paragangliomas [24,25]. Around 20% of SDHB mutation carriers
will develop metastatic disease [12,25]. SDHB mutations tend to show
low penetrance and only 25–40% of all carriers will eventually develop
a tumor [26–28], suggesting that many carriers go undetected. This is
reﬂected in the apparently sporadic presentation of many patients
[29], with further investigation of family members often revealing
germline mutations in asymptomatic carriers, many of whom remain
tumor-free to advanced age [26]. Although the underlying cause of re-
duced penetrance is unknown, possible genetic explanations include in-
hibition of cell proliferation due to secondary loss of vital genetic
material in the proximity of the remaining normal allele or that addi-
tional loss of chromosome 11 is required (Hensen model) [23,30].2.3. SDHC
Despite the close physical interaction of the SDHCand SDHDproteins,
paragangliomas due to SDHC mutations are far less common than
SDHD-related paragangliomas. Although the number of SDHC-related
patients is still insufﬁcient to allow ﬁrm conclusions to be drawn, the
penetrance of SDHCmutations appears to be low, more closely reﬂecting
that of SDHB than SDHD. The clinical expression of SDHC mutations ap-
pears to be comparable to that of SDHD however, with most patients
showing primarily head and neck paragangliomas, although some sym-
pathetic paragangliomas have been reported [31,32].2.4. SDHA
The identiﬁcation of mutations of complex II in hereditary
paraganglioma–pheochromocytoma syndrome immediately implied a
role for the major catalytic subunit, SDHA. Initial research efforts were
stymied by confusion as to the extent and nature of possible additional
copies of the SDHA gene [33], and over a decade would elapse before aTotal no. pathogenic mutations Pathogenic mutations by disease
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paraganglioma [34].
An apparent theme of SDH mutations, that the number of identi-
ﬁed mutations varies widely and is unrelated to the size of the pro-
tein, is continued with the largest protein of complex II, SDHA. Only
three PGL/PC-associated mutations have been identiﬁed to date,
even less than for Leigh syndrome. Nonsense SDHA mutations have
been convincingly associated with disease through biochemical anal-
ysis, but the same mutations have been found at a relatively high fre-
quency in healthy controls (0.5%). This suggests that SDHAmutations
may show extremely low penetrance [35], with most mutation car-
riers escaping the development of clinical symptoms. SDHA is the
most stable of the SDH proteins when soluble and also appears to
be a component of a mitochondrial ATP-sensitive potassium channel
[36]. This additional function could be an explanation for the rarity
of mutations if maintenance of this complex is essential for cell viabil-
ity, although this supposition is challenged by the existence of Leigh
syndrome patients with homozygous SDHA mutations.
An alternative, genetic explanation might be that the ‘second hit’,
usually occurring via complete or partial chromosomal loss, would re-
sult in the concomitant loss of essential genes in the proximity of
SDHA. If these genes are essential to cell viability, only very speciﬁc
and rare molecular events may be tolerated. This concept does not ex-
plain the lack of somatic mutations however.
2.5. SDHAF2
A recently identiﬁed, novel paraganglioma-related gene encodes a
protein involved in the addition of a ﬂavin-adenine dinucleotide
(FAD) prosthetic group to form the active SDHA ﬂavoprotein. Loss of
succinate dehydrogenase complex assembly factor 2 (SDHAF2) leads
to reduced complex II stability, reduced levels of all subunits and loss
of function, demonstrating that correct ﬂavination of SDHA is essential
for complex II function [15]. Despite this close functional relationship
with a catalytic subunit of complex II, loss of SDHAF2 results in a
SDHD-like phenotype, with a highly penetrant and exclusively head
and neck paraganglioma phenotype [37,38]. Another striking similarity
with SDHD is the expression of exclusively paternal mutations; no car-
rier of a maternally transmitted SDHAF2 mutation has ever developed
a tumor. Although the mechanistic basis of this clinical phenotype and
mode of inheritance is unknown, it accords with and is predicted by
the ‘Hensen model’ [20].
2.6. Mutations
Mutations in genes associated with complex II are summarized in
the TCA Cycle Gene Mutation Database (http://chromium.liacs.nl/
lovd_sdh). Although we have not yet added SDHAF1, we plan do so in
the near future.
Around 15% of all paragangliomas are attributable to mutations in
genes associated with complex II (SDHA, SDHB, SDHC, SDHD and
SDHAF2) [25,34,38]. All of these genes are thought to have a tumor
suppressor function and most tumors show genetic loss of the normal
allele in conjunction with a germline mutation, resulting in the loss of
the speciﬁc protein subunit that in turn destabilizes complex II and
reduces or abolishes enzymatic activity [39–41].
For unknown reasons, there is wide variation in the number of
unique mutations reported for each subunit gene. SDHB predominates,
with 186 pathogenic mutations listed in the TCA Cycle Gene Mutation
Database, followed by SDHD (n=119), SDHC (n=35), SDHA (n=15,
and mainly associated with LS) and SDHAF2 (n=2) [42]. In addition
to the widely differing frequency of mutations, the phenotypes
resulting from SDHmutations showdifferences in tissue-speciﬁcity, be-
havior and penetrance. Current understanding of the biology of com-
plex II offers no ready explanation for these differences.3. Gastrointestinal stromal tumors
Gastrointestinal stromal tumors (GISTs) are rare mesenchymal
tumors of the gastrointestinal tract, and while generally diagnosed
around the age of 60, tumors may occur in children or young adults in
association with familial syndromes including Carney triad (GIST,
paraganglioma, pulmonary chondroma) and Carney–Stratakis syn-
drome (GIST, paraganglioma). Around two-thirds of GISTs occur in the
stomach, with the remaining cases occurring in the esophagus and
throughout the gastrointestinal tract [43]. Originally considered to be
of smooth muscle origin, GISTs are now thought to originate from the
pacemaker cells regulating digestive tract peristalsis, the so-called
‘interstitial cells of Cajal’ (ICCs) [44]. Most GISTs carry somatic
gain-of-function mutations in the KIT gene and non-KIT tumors often
harbor similar mutations in the platelet derived growth factor
receptor-a (PDGFRA) gene [45–47] or may occur in neuroﬁbromatosis
type 1 patients [48].
3.1. Pediatric wild type GISTs
GISTs in children and young adults appear to be a distinct clinical
entity and are referred to as ‘pediatric wild type GISTs’ [49]. Together
with an absence of KIT/PDGFRA mutations, these tumors show several
other characteristic features including occurrence exclusively in the
stomach, a multinodular growth pattern and a propensity to metasta-
size [50,51]. Pediatric wild type GISTs show similar clinical features
and morphology to GISTs that occur together with paragangliomas.
The Carney triad is a rare and sporadic tumor syndrome of unknown
etiology, chieﬂy affecting young adult females, and showing a
co-occurrence of GISTs, pulmonary chondromas and/or extra-adrenal
paragangliomas [52]. The closely related Carney–Stratakis syndrome is
a very rare condition showing a co-occurrence of KIT-negative GIST
and familial paraganglioma. The ﬁrst report of this syndrome described
12 young patients (average age of 23 years) from ﬁve unrelated fami-
lies. These patients showed multifocal and frequently metastatic
GISTs, with multicentric paragangliomas [53]. A genetic basis for
Carney–Stratakis syndrome was subsequently elucidated with the dis-
covery of germline mutations in the SDHB, SDHC and SDHD genes in
8 of the 11 cases tested [54].
More recently, Pantaleo et al. reported the discovery of SDHAmuta-
tions in two young adults with wild type GISTs [55] and subsequently
reported a further two patients [56]. Interestingly, all cases showed
germline or somatic point mutations affecting both alleles, rather than
the gross chromosomal losses more typical of tumor suppressor genes.
3.2. SDHB immunohistochemistry
While germline SDH mutations have been found in only a subset of
GISTs, loss of SDHB protein expression is relatively common in WT
GISTs. In 2010, Gill et al. reported that both Carney triad associated
GISTs and a pediatric GIST showed negative immunohistochemical
staining for SDHB, while 97% of sporadic GISTs were positive [49].
Other studies conﬁrmed and extended this ﬁnding, showing that
‘SDH deﬁcient GISTs’ are also associated with Carney–Stratakis and a
fraction of apparently sporadic adult wild type GISTs. Janeway et al.
evaluated 30 WT GIST tumors without associated SDH mutations and
found loss of SDHB protein expression in all 18 pediatric WT GISTs
tested, andweak or absent expression in all 12 adultWTGISTs. For com-
parison, only 1 of 23 KIT or NF-1-associated GISTs showed loss of SDHB
expression. Loss of SDHB expression suggests that complex II enzyme
activity will also be affected and these authors showed that two WT
GISTs without an associated SDHmutation also lacked enzyme activity.
Janeway and colleagues investigated several possible mechanisms of
SDHB loss including decreased mRNA expression of SDHB, SDHC, or
SDHD due to epigenetic modiﬁcations and loss of function mutations
in the SDHA or SDHAF2 genes, but found no evidence for either
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GISTs among 756 gastric GISTs (7.5%) and noted thatmost gastric GISTs
in patients b20 years and a substantial percentage in patients
b40 years were SDH deﬁcient. Very few SDHB-negative tumors were
seen in older cases, and all non-gastric GISTs (n=378) were SDHB pos-
itive [58].
Negative SDHB immunohistochemistry is an established and reliable
means of identifying pheochromocytomas and paragangliomas caused
by SDH mutations, and now appears to be relevant to a speciﬁc group
of GISTs. Gaal et al. explored the relationship between SDHB immuno-
histochemistry and SDHmutations in four GISTs from Carney–Stratakis
syndrome patients and six from Carney triad patients, together with 42
apparently sporadic GISTs. Negative SDHB immunohistochemistry was
followed by mutational analysis of SDHB, SDHC, and SDHD. All Carney–
Stratakis and Carney triad syndrome GISTs stained negative for SDHB,
but a germline mutation (SDHB) was found in only one patient. Of the
42 sporadic tumors, only one was SDHB-negative and no mutation
was detected in this tumor [59].
The loss of SDHB expression and lack of complex II activity suggests
that defects in complex II or cellular respiration may play an important
oncogenic role in a particular subset of GISTs. The SDH mutations
reported in some of these tumors are clearly pathogenic and thus can
be assumed to be causative, but the absence of mutations in most
cases suggests thatmechanisms of complex II deactivation of amore ge-
neric nature must also be at play. SDH-deﬁcient GISTs now appear to
represent a distinctive tumor type, with a speciﬁc morphology and set
of associated clinical features including an exclusive localization to the
stomach, amultilobulated growthpattern, frequent but indolentmetas-
tases, and occurrence in children and young adults [60].
4. Renal cell carcinoma
The most common type of renal cell carcinoma (RCC) is clear cell
RCC (ccRCC), a tumor of the renal cortex characterized by tumor cells
with a clear cytoplasm and a well-vascularized, nested growth pattern.
Other non-clear cell types include the papillary, type II papillary,
collecting duct and chromophobic tumors [61]. Only 3–4% of all cases
of RCC are hereditary and these are attributable to mutations in a het-
erogeneous collection of genes including VHL, MET, TSC1, TSC2, FH
and FLCN. A wide variety of genotype–phenotype correlations have
been described in familial RCC, and the most prominent include the as-
sociation of VHLmutationswith ccRCCs, METwith type 1 papillary RCC,
and FH with type 2 papillary RCC [62,63]. VHL is the most common
cause of inherited ccRCC and accounts for around 30% of all cases [61].
4.1. SDHB
More recently, mutations in subunit genes of complex II have been
recognized to confer risk for RCC, indicating that RCC should be now
be included, together with GIST, in the spectrum of tumors associated
with pheochromocytoma-paraganglioma (PGL) syndrome [49,64–66].
The association of RCC with SDHmutations was not entirely unexpect-
ed, as both VHL and FH have strong mechanistic links to SDH. The
SDH-related development of RCC currently appears to be dominated
by germline DNA mutations of SDHB.
The association of germline SDHB mutations with renal tumors was
ﬁrst described by Vanharanta et al. (2004), who reported two families
with early-onset RCC and germline SDHBmutations. The ﬁrst family in-
cluded two members with both early-onset RCC and paraganglioma.
The second family comprised a patient diagnosed with ccRCC and his
mother was diagnosed with malignant paraganglioma, both of whom
carried a germline SDHB mutation [66]. That hereditary RCC can occur
without any personal or family history of pheochromocytoma or
paraganglioma was shown when Ricketts et al. [65] described germline
SDHB mutations in RCC-only cases. These studies suggest that geneticscreening for germline SDHBmutations should be considered in patients
with familial RCC.
4.2. Histopathologic subtypes
There are no clear correlations of histopathologic subtypes of RCC
with germline SDHB mutations and the most frequently reported
SDHB-associated renal tumors are also the most common, the ccRCCs.
A variety of other types of renal tumors have been described in patients
with SDHB mutations, including chromophobic RCC, type II papillary
RCC, and oncocytoma [65–68]. Housley et al. [69] reported a morpho-
logically unique renal tumor associated with a germline SDHBmutation
and described distinctive intracytoplasmic inclusions, demonstrating
that these inclusions represent giant mitochondria. This study was
followed by Gill et al. [64] who described the morphology and clinical
features of renal tumors associated with germline SDHB mutations.
These tumors displayed eosinophilic cytoplasm with intracytoplasmic
inclusions and indistinct cell borders, reminiscent of the morphological
features described by Housley et al., suggesting that giant mitochondria
may be a key morphologic feature of SDHB-associated renal tumors.
However, these morphological features have not been described for
all SDHB-associated renal tumors, although this might be due to lack
of detailed analysis. Ultrastructural analysis of paragangliomas has
shown that giant mitochondria are also a feature of this tumor, but
this characteristic is also often overlooked [40].
A recent report suggests that SDHCmutationsmay also be associated
with RCC. Malinoc et al. [70] investigated known carriers of germline
SDHC mutations for renal tumors, and found one patient with
both a PGL and two RCCs. Molecular investigation of the tumors,
metachronous bilateral ccRCCs and a papillary RCC, revealed no somatic
SDHCmutations but did show LOHof intragenic andﬂankingmarkers at
the SDHC locus. SDHB immunostaining showed that the two ccRCCs
were negative but the papillary RCC stained positive for SDHB, perhaps
suggesting that this tumor was coincidental [70]. Further studies are
needed to conﬁrm these ﬁndings.
5. Leigh syndrome and cardiomyopathy
Leigh syndrome (LS) is a progressive neurodegenerative disorder
of infancy or childhood and is characterized by diverse neuropatho-
logic features including focal, necrotizing lesions of the basal ganglia,
diencephalon, cerebellum, or brainstem. The clinical hallmarks of LS
vary but may include psychomotor delay or regression, muscular hy-
potonia, ataxia, respiratory insufﬁciency, and tremor due to lactate
academia [71]. There is currently no effective treatment for LS and
many patients die within months of being diagnosed. LS is a geneti-
cally heterogeneous disease and mutations in complexes I–V of the
respiratory chain, coenzyme Q, and the pyruvate dehydrogenase
complex all lead to a deterioration in mitochondrial function. Deﬁ-
ciencies of complex II are particularly rare and account for around
2% of all respiratory chain deﬁciencies [72].
5.1. SDHA
Bourgeron et al. (1995) described the ﬁrst mutation in a nuclear
encoded subunit of complex II. Two siblings with LS and a deﬁciency
of complex II both carried a homozygous missense mutation in the
SDHA gene. The parents were ﬁrst cousins and both were heterozygous
carriers of themutation [71]. Both patients presentedwith neurological
signs after the age of 10 months and showed developmental regression
over the following months. Increased levels of serum lactate were
detected andmagnetic resonance imaging (MRI) showed abnormalities
characteristic for LS in the cerebral white matter and basal ganglia.
The second patient with a mutation in complex II and a complex II
deﬁciency was described by Parfait et al. (2000). In this case the pa-
tient was born to unrelated parents and developed normally until
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mental abnormalities were apparent by 16 months of age, and mildly
elevated lactate was also noted. MRI revealed necrotic lesions in the
basal ganglia, conﬁrming the diagnosis of LS. Enzyme analyses identi-
ﬁed a complex II defect and showed complex activity of a third of nor-
mal levels. The patient was found to carry compound heterozygous
mutations in the SDHA gene, including a nonsense mutation affecting
the translation initiation codon and a missense mutation [72].
A report by Van Coster et al. (2003) described a patient, born to ﬁrst
cousins, with lowweight gain at 5 months. A hospital admission due to
respiratory difﬁculties revealed poormuscle tone, and an enlarged liver
and spleen. An additional enlargement of the heart and serious cardiac
dysrythmia resulted in the death of the patient during the ﬁrst day of
hospitalization. Although the patient was too young to allow assess-
ment of LS symptoms, genetic analysis identiﬁed a homozygous
missense mutation of SDHA [73]. The same homozygous missense mu-
tationwas reported in a patient with a relatively mild LS and complex II
deﬁciency phenotype [74]. This patient, also born toﬁrst cousin parents,
initially showed normal developmental but by 22 months, myopathy,
poorwalking and frequent falls were apparent. Further examination re-
vealed elevated blood lactate and abnormalities on brainMRI. However,
the patient then showed a gradual improvement and by the age of 10
could occasionally walk up to 200 m. He also showed a lack of cognitive
impairment and repeat MRI demonstrated no new lesions and im-
provements in previous abnormalities [74].5.2. Cardiomyopathy
Dilated cardiomyopathy is characterized by impaired systolic func-
tion due to dilatation of the left or both ventricles and is a major cause
of morbidity and death, due to sudden cardiac arrest. Levitas et al. [75]
described 15 Bedouin patients from a single tribe who all presented
with dilated cardiomyopathy. Despite a mild increase in lactate, all pa-
tients had normal growth, normal muscle bulk and strength, and nor-
mal reﬂexes and gait. The psychomotor development of all patients
was also normal and none had seizures. LS was ruled out as a diagnosis
by brain MRI. Eight infants were diagnosed with left ventricular
non-compaction (LVNC), a condition characterized by an incomplete
development of the heart. Assessment of respiratory chain enzymes in
skeletal and cardiac muscle biopsies showed a 50–60% reduction in
complex II activity in skeletal muscle but an up to 85% reduction in car-
diac muscle. A homozygous missense mutation in the SDHA gene,
p.Gly555Glu, was identiﬁed in all patients. While this mutation caused
only cardiomyopathy in these patients, the same mutation has also
been reported in connection with myopathy, cardiomyopathy and
mild Leigh-like symptoms [73,74].
Horvath et al. [76] described a case of a child of unrelated parents
showing developmental delay and muscle weakness at 5 months of
age, but with a normal heart and abdominal organs. Electroencephalog-
raphy (EEG) showed some irregularities, lactate levels were mildly in-
creased, and the child developed spasticity and other abnormalities. By
the age of 9 the patient showed psychomotor arrest, blindness, seizures,
and severe muscle contractures. Biochemical analysis of muscle biopsy
specimens showed a residual complex II activity of only 23%. Sequencing
of SDHA identiﬁed compound heterozygote mutations, including both a
nonsense and a missense mutation.
More recently, Alston and colleagues described a patient with com-
pound heterozygous mutations in the SDHA gene (p.Thr508Ile;
p.Ser509Leu). At 3 months of age he presented with increasing short-
ness of breath, sweating, and feeding difﬁculty. Cardiomegaly and is-
chemia were evident, with a dilated and enlarged left ventricle, and
hewas diagnosed with dilated cardiomyopathy. In addition, the patient
developed motor delay, knee and hip contractures, and generalized
muscle weakness. Cranial and spinal MRI at 2.5 years age also demon-
strated extensive abnormalities. A muscle biopsy revealed severelyreduced SDHactivity and BN/SDS-PAGE analysis showed loss of fully as-
sembled complex II and SDHA protein [77].
5.3. Late-onset disease
A remarkable exception to the early onset seen in most cases of mi-
tochondrial deﬁciency was reported by Birch-Machin et al. These au-
thors described an autosomal dominant condition in a family with
several affected cases, all ofwhomcarried a heterozygousmissensemu-
tation of SDHA [78]. Patients showed an approximately 50% decrease in
both complex II and SDH activity, and an unusual phenotype of
late-onset neurodegenerative disease characterized by progressive
optic atrophy, ataxia, and myopathy. While these ﬁndings suggest that
a 50% reduction in SDHA RNA and protein content (haploinsufﬁciency)
can result in a clinically relevant complex II deﬁciency and late-onset
neurodegenerative disease, it is worth noting that the parents of the ju-
venile cases described above also carry heterozygous mutations but
have not been reported to develop clinical symptoms.
5.4. Clinical and metabolic diversity
These ﬁndings illustrate the diversity of SDHA-related phenotypes
that can result from similar or even identical mutations, with homozy-
gous mutations resulting in phenotypes ranging from devastating
developmental abnormalities to a purely cardiovascular phenotype –
free of neurological involvement – and heterozygousmutations leading
to late-onset neurodegenerative disease. While the basis of this clinical
diversity is unknown, a clue may have been provided by Levitas et al.
who described a healthy carrier of homozygous SDHA mutations [75].
This individual was the father of one of the patients but in contrast to
his son, he exhibited normal LV function and dimension and was nor-
mal on clinical assessment, despite having lost three young siblings to
cardiovascular failure. He was also capable of heavy physical work,
while still showing complex II activity levels similar to those of the clin-
ical cases. This apparent metabolic adaptation might have a genetic
basis, but the child described by Pagnamenta et al. suggests that some
physiological adaptation may also take place [74].
While the heterozygous patients described by Birch-Machin et al.
developed late-onset disease, the lack of clinical symptoms in parents
of homozygous patients could be due to mutation-speciﬁc effects, al-
though the structure of SDHA and the range of known mutations sug-
gest otherwise. It is worth noting that all patients show residual
complex II activity and mutations are predominantly missense, with
nonsense mutations only occurring when accompanied by a missense
mutation [76], suggesting that complete loss of SDHA protein func-
tion may be incompatible with life. The molecular defects resulting
from complex II deﬁciencies are still rather poorly understood, but
both oxidative phosphorylation and the TCA cycle show dysfunction,
and hypoglycemia and lacticacidemia are commonly seen in patients
[71,76].
The heterozygous parents of homozygous SDHA mutation carriers
are also theoretically prone to paraganglioma development, as muta-
tions of SDHA have been shown to be a (rare) cause of paraganglioma.
However, the extreme rarity of SDHA-related tumors may be due to
the relatively low frequency of the loss of the chromosomal region
containing the SDHA locus (5p15), compared with the 1p36 (SDHB)
and 11q23 (SDHD) loci that often show loss in tumor tissues [34].
On the other hand, the neurodegenerative disorders and cardiomyop-
athies associated with SDHA have not (yet) been linked to mutations
in the SDHC or SDHD genes. This may be due to the structural role of
the SDHC and SDHD proteins, with pathogenic mutations resulting in
complete rather than partial loss of function. Such mutations may be
poorly tolerated and incompatible with life in a homozygous state,
while missense mutations with relatively mild affects on the catalytic
functions of SDHA or SDHB can occur in a homozygous state. The role
of haploinsufﬁciency for individual components of complex II may
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or -D genes results in no noticeable physiological phenotype, while
heterozygous mutations of SDHA, accompanied by reduced enzymatic
activity, can give rise to late-onset neurodegenerative disease [78].
6. Infantile leukodystrophies
6.1. SDHAF1
A speciﬁc infantile leukoencephalopathy was recently identiﬁed in
several cases in two large, unrelated consanguineous families [79]. Clin-
ical features in both families were very similar and further investigation
revealed elevated blood lactate and pyruvate levels. Further character-
istics included an initial 6–11 month disease-free interval followed by
a rapidly progressive psychomotor regression, weakness of all four
limbs, loss of postural control, and involuntary muscle contractions.
MRI of the brain showed severe changes to the brain white matter,
and accumulation in the brain of lactate and succinate was also
detected. Patient muscle and ﬁbroblasts showed only 20–30% residual
complex II activities. The clinical condition of the patients stabilized
and while showing consistently impaired growth, several patients sur-
vived for over a decade.
Genetic mapping using linkage analysis identiﬁed a common homo-
zygous region on chromosome19 and further analysis identiﬁed homo-
zygous mutations in a previously unknown gene, now called succinate
dehydrogenase complex assembly factor 1 (SDHAF1) [79]. The encoded
protein is ubiquitously expressed in mitochondria, and although
novel, it carries a tripeptide LYRmotif found in several proteins involved
in Fe–S metabolism. SDHAF1 may therefore be associated with SDHB
and involved in the insertion or retention of the complex II Fe–S center.
Other Fe–S-dependent activities tested in SDHAF1-defective organisms
were normal, implying that SDHAF1 may be speciﬁc for complex II.
The association of mutations of SDHAF1 with an infantile
leukoencephalopathy reminiscent of Leigh syndrome was somewhat
unexpected – as was the association of mutations of SDHAF2 with
paraganglioma – because these co-factors interact with complex II
subunits that generally give very different phenotypes when mutated.
If SDHAF1 is a cofactor of SDHB, heterozygous mutations might be
expected to result in typical SDHB-associated tumors including
paraganglioma, pheochromocytoma, GIST and renal cell carcinoma,
while the SDHA cofactor SDHAF2 would be predicted to give rise to
extra-adrenal paraganglioma, GIST and Leigh syndrome (when homozy-
gously mutated). Although such clinical phenotypes may yet come to
light, at themoment it appears thatwe still havemuch to learn regarding
the cofactors of complex II.
6.2. SDHB
More recently, Alston and colleagues described a female child, born
to consanguineous parents, who showed apparently normal develop-
mental to 1 year of age, but then regressed rapidly over a 6-week period
[77]. In addition to unsteadiness, repeated falls, and eventual loss of
walking ability, the child showed loss of muscle tone with poor head
control and difﬁcult feeding. Following this period of deterioration,
the child showed slow developmental progress but remained
wheelchair-dependent at the age of 4 years. MRI demonstrated leuko-
dystrophy of deep cerebral whitematter at both the initial presentation
and at 4.5 years, with dystrophic white matter showing increased lac-
tate and succinate.
A diagnostic muscle biopsy showed severely reduced SDH and com-
plex II activity, and genetic analysis identiﬁed a novel homozygousmu-
tation in the SDHB gene (c.143A>T, p.Asp48Val). Further investigations
showed an almost complete absence of the SDHB subunit by SDS-PAGE
analysis, and studies of the equivalent mutation in yeast showed a 50%
reduction in SDH activity.Aswell as being the ﬁrst association of an SDHB defect with a neuro-
logical phenotype, this ﬁnding represents the ﬁrst description of a ho-
mozygous SDHB mutation in any patient (or in any multicellular
organism, for that matter). Although no systematic functional study of
the effect of putativemutations of SDH subunits has yet been described,
several studies have focused on speciﬁc subunits and certain variants
[80–82]. An earlier study may provide a clue as to why the p.Asp48Val
mutation can exist in a homozygous state [83]. Goffrini and colleagues
have previously studied a p.Cys191Tyr mutation, found in a patient
with head and neck paraganglioma, and could show that the ability of
the yeast strain, BY4741Δsdh2, to grow on 2% ethanol could not be
complemented by the mutation (sdh2C184Y), whereas the growth of
the p.Asp48Val (sdh2N42V) strainwas almost equivalent to complemen-
tationwith awild type construct. Equally, the sdh2C184Y strain showed a
profound defect in respiration, while the sdh2N42V strain showed no
change. The 50% reduction in SDH activity seen in the sdh2N42V strain
also contrasted with the approximately 95% reduction seen in the
sdh2C184Y strain.
These differences, although only broadly concordant with the de-
clines in complex II activity seen in muscle biopsies, may suggest that
the p.Asp48Val variant induces relatively minor changes in the SDHB
protein compared to the paraganglioma-associated p.Cys191Tyr mu-
tation. Only time will tell if further SDHB variants will emerge with
an ‘intermediate’ genetic phenotype and an association with neuro-
logical disorders.
7. Conclusions
Defects in complex II lead to a diverse array of clinical symptoms,
ranging from serious developmental delay to tumors as varied as
renal cell carcinoma and paraganglioma. Is there a common theme
that unites these clinical syndromes? One broad theme that is per-
haps fundamental to all these diseases, and also a ‘new frontier’ for
the understanding of disease in general, is that of cell speciﬁcity.
Cell types show profound differences that often survive cancerous
transformation, and during development and throughout life cells
differ in their requirements for ATP, redox agents and the metabolic
intermediates produced by the TCA cycle. These differences may
make certain cells particularly vulnerable to complex II-mediated
transformation and neoplasia. Cardiac cells and cells of the ascending
and descending tubules of the kidney have a heavy energy dependen-
cy and show a high level of expression of complex II; tumorigenic
cells of paragangliomas, pheochromocytomas and GISTs all have a
neuronal function. These similarities may be coincidental but might
hint at some underlying commonality.
7.1. Biochemical studies
Despite considerable progress in understanding the biochemistry
resulting from loss of complex II [84,85], no direct link to tumorigenesis
has yet been established. We still do not know if the primary link be-
tween loss of complex II and tumorigenesis is due to the activation of
HIF1 through the accumulation of succinate [86,87], due to the genera-
tion of ROS [3] or to other mechanisms such as inhibition of histone
demethylases [88] or inhibition of EglN3-mediated apoptosis [89].
While one or more of these mechanisms may be important, studies
have been contradictory. Loss of SDH has been shown to lead to oxida-
tive stress and genomic instability by inducing a pseudo-hypoxic re-
sponse [3,4,80,90,91]. Conversely, other studies reported no signs of
ROS production or oxidative stress resulting from SDH mutations, but
rather an accumulation of succinate and HIF1a activation [5,92].
7.2. Animal and cell models
Elucidating the primary link between loss of complex II and dis-
ease is an important clinical aim that could open the way to new
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implicated in disease, no direct causal link to disease has yet been
established. A major barrier to further progress is the current lack of
relevant animal and cell models. Although several mouse lines carry-
ing knockouts of SDH genes have been described, heterozygous ani-
mals do not develop disease and homozygous knockout is lethal
[93,94]. Conditional and tissue-speciﬁc models also fail to develop
disease [95] (and unpublished results). To date, no cell line from a
paraganglioma or other complex II-related tumor has been described.
Until these models are established the resolution of currently
conﬂicting data and further progress towards potential therapies
will remain beyond our reach.
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